Moreover, more studies that compared both OS and PFS between erlotinib and gefitinib in stage IV exon 19 EGFR-mutant lung adenocarcinoma patients after completion of all standard adjuvant chemotherapy and/or radiation therapy also showed similar outcomes [5, 12, 21]. This evidence concerns the gene EGFR and lung adenocarcinoma.